IP Library › Assignment 058604/0004

Patent Assignment

Reel/Frame 058604/0004

Assignment of Assignor's Interest

Recorded: 2021-12-28 Pages: 36

View PDF Order Certified Copy

Assignor

JANSSEN BIOTECH, INC.

Executed: 2021-11-16

Assignee

ARAXES PHARMA LLC

3033 SCIENCE PARK ROAD, SUITE 220, SAN DIEGO, CALIFORNIA, 92121

Covered Properties (107)

Irreversible covalent inhibitors of Kras G12C

Application: 61/852,285 →

Irreversible Covalent Inhibitors of Kras G12C

Application: 61/889,328 →

Irreversible Covalent Inhibitors of the Gtpase K-Ras G12C

Patent: 9,745,319 →

Application: 14/777,334 →

Publication: US 2016/0031898

Covalent Inhibitors of Kras G12C

Patent: 9,227,978 →

Application: 14/212,656 →

Publication: US 2014/0288045

Covalent Inhibitors of Kras G12C

Patent: 9,926,267 →

Application: 14/933,734 →

Publication: US 2016/0159738

Covalent Inhibitors of Kras G12C

Patent: 10,273,207 →

Application: 15/891,304 →

Publication: US 2018/0162812

Covalent Inhibitors of Kras G12C

Patent: 10,919,850 →

Application: 16/355,258 →

Publication: US 2019/0389796

Covalent inhibitors of KRAS G12C

Application: 61/852,123 →

Covalent Inhibitors of Kras G12C

Application: 61/889,480 →

Substituted Quinazolines as Inhibitors of Kras G12C

Patent: 9,840,516 →

Application: 14/511,425 →

Publication: US 2015/0239900

Substituted Quinolines as Inhibitors of Kras G12C

Patent: 10,370,386 →

Application: 15/805,716 →

Publication: US 2018/0118757

Substituted Cinnolines as Inhibitors of Kras G12C

Patent: 10,927,125 →

Application: 16/449,967 →

Publication: US 2020/0102321

Substituted Quinazolines as Inhibitors of Kras G12C

Patent: 11,878,985 →

Application: 17/125,955 →

Publication: US 2021/0188869

Inhibitors of Kras G12C

Application: 61/889,460 →

Inhibitors of Kras G12C

Application: 62/034,619 →

Inhibitors of Kras G12C

Application: 62/052,366 →

Combination Therapies for Treatment of Cancer

Patent: 10,111,874 →

Application: 14/858,766 →

Publication: US 2016/0166571

Combination Therapies for Treatment of Cancer

Application: 16/141,775 →

Publication: US 2019/0262342

Combination Therapies for Treatment of Cancer

Application: 62/052,332 →

Combination Therapies for Treatment of Cancer

Application: 62/195,633 →

Inhibitors of Kras G12C Mutant Proteins

Application: 62/055,188 →

Inhibitors of Kras G12C Mutant Proteins

Patent: 9,862,701 →

Application: 14/866,147 →

Publication: US 2016/0108019

Inhibitors of Kras G12C Mutant Proteins

Application: 15/817,075 →

Publication: US 2018/0141927

Inhibitors of Kras G12C Mutant Proteins

Application: 62/233,556 →

Inhibitors of Kras G12C Mutant Proteins

Patent: 10,858,343 →

Application: 15/763,802 →

Publication: US 2018/0273515

Inhibitors of Kras G12C Mutant Proteins

Application: 62/233,632 →

Inhibitors of Kras G12C Mutant Proteins

Patent: 10,647,703 →

Application: 15/763,798 →

Publication: US 2018/0282307

Inhibitors of Kras G12C Mutant Proteins

Application: 62/233,597 →

Inhibitors of Kras G12C Mutant Proteins

Patent: 10,730,867 →

Application: 15/763,806 →

Publication: US 2018/0273523

Inhibitors of Kras G12C Mutant Proteins

Application: 62/233,815 →

Inhibitors of Kras G12C Mutant Proteins

Patent: 10,882,847 →

Application: 15/763,812 →

Publication: US 2018/0282308

Inhibitors of Kras G12C Mutant Proteins

Application: 62/233,595 →

Inhibitors of Kras G12C Mutant Proteins

Patent: 10,875,842 →

Application: 15/764,076 →

Publication: US 2018/0319775

Inhibitors of Kras G12C Mutant Proteins

Application: 62/233,816 →

Inhibitors of Kras G12C Mutant Proteins

Patent: 10,689,356 →

Application: 15/764,088 →

Publication: US 2019/0055211

Inhibitors of Kras G12C Mutant Proteins

Application: 62/233,814 →

Inhibitors of Kras G12C Mutant Proteins

Application: 62/342,040 →

Inhibitors of Kras G12C Mutant Proteins

Patent: 10,975,071 →

Application: 15/764,097 →

Publication: US 2019/0092767

Substituted Quinazoline Compounds and Methods of Use Thereof

Application: 62/145,705 →

Substituted Quinazoline Compounds and Methods of Use Thereof

Application: 62/255,891 →

Substituted Quinazoline Compounds and Methods of Use Thereof

Patent: 10,246,424 →

Application: 15/093,951 →

Publication: US 2016/0297774

Substituted Quinazoline Compounds and Methods of Use Thereof

Patent: 10,829,458 →

Application: 16/281,905 →

Publication: US 2019/0284144

Substituted Quinazoline Compounds and Methods of Use Thereof

Application: 62/145,818 →

Substituted Quinazoline Compounds and Methods of Use Thereof

Application: 62/265,320 →

Fused-Tricyclic Inhibitors of Kras and Methods of Use Thereof

Application: 62/147,955 →

Fused-Tricyclic Inhibitors of Kras and Methods of Use Thereof

Patent: 10,428,064 →

Application: 15/566,648 →

Publication: US 2018/0086753

Substituted Quinazoline Compounds and Methods of Use Thereof

Application: 62/195,636 →

Substituted Quinazoline Compounds and Methods of Use Thereof

Application: 62/342,078 →

Substituted Quinazoline Compounds and Methods of Use Thereof

Patent: 10,144,724 →

Application: 15/217,304 →

Publication: US 2017/0022184

Substituted Quinazoline Compounds and Methods of Use Thereof

Patent: 10,351,550 →

Application: 15/916,075 →

Publication: US 2018/0194748

Methods for Preparation of Quinazoline Derivatives

Application: 62/265,303 →

Methods for Preparation of Quinazoline Derivatives

Patent: 9,988,357 →

Application: 15/373,832 →

Publication: US 2017/0190672

2-Substituted Quinazoline Compounds Comprising a Substituted Heterocyclic Group and Methods of Use Thereof

Patent: 10,414,757 →

Application: 15/353,402 →

Publication: US 2017/0197945

2-Substituted Quinazoline Compounds Comprising a Substituted Heterocyclic Group and Methods of Use Thereof

Patent: 11,021,470 →

Application: 16/514,675 →

Publication: US 2020/0181123

2-Substituted Quinazoline Compounds Comprising a Substituted Heterocyclic Group and Methods of Use Thereof

Application: 62/255,879 →

2-Substituted Quinazoline Compounds Comprising a Substituted Heterocyclic Group and Methods of Use Thereof

Application: 62/340,291 →

2-Substituted Quinazoline Compounds Comprising a Substituted Heterocyclic Group and Methods of Use Thereof

Application: 62/406,247 →

Substituted Quinazoline Compounds and Methods of Use Thereof

Application: 62/265,316 →

Conjugates of Cereblon Binding Compounds and G12C Mutant Kras, Hras or Nras Protein Modulating Compounds and Methods of Use Thereof

Application: 62/361,810 →

Conjugates of Cereblon Binding Compounds and G12C Mutant Kras, Hras or Nras Protein Modulating Compounds and Methods of Use Thereof

Patent: 10,646,488 →

Application: 15/649,568 →

Publication: US 2018/0015087

Substituted Isoquinolinone and Isoindolinone Compounds and Methods of Use Thereof

Application: 62/405,701 →

Inhibitors of Ras and Methods of Use Thereof

Application: 62/450,966 →

Inhibitors of Ras and Methods of Use Thereof

Patent: 10,377,743 →

Application: 15/727,422 →

Publication: US 2018/0127396

Inhibitors of Kras G12C Mutant Proteins

Application: 62/401,345 →

Inhibitors of Kras G12C Mutant Proteins

Patent: 10,280,172 →

Application: 15/721,021 →

Publication: US 2018/0155348

Inhibitors of Kras G12C Mutant Proteins

Patent: 10,723,738 →

Application: 16/374,356 →

Publication: US 2020/0062761

Inhibitors of Ras Mutant Proteins and Methods of Use Thereof

Application: 62/450,914 →

1-(3-(6-(3-Hydroxynaphthalen-1-Yl)Benzofuran-2-Yl)Azetidin-1 Yl)Prop-2-En-1-One Derivatives and Similar Compounds as Kras G12C Modulators for Treating Cancer

Patent: 11,279,689 →

Application: 16/480,195 →

Publication: US 2019/0382377

Substituted Quinazoline and Quinazolinone Compounds and Methods of Use Thereof

Application: 62/450,939 →

Substituted Quinazoline and Quinazolinone Compounds and Methods of Use Thereof

Patent: 11,136,308 →

Application: 16/480,205 →

Publication: US 2020/0010454

Fused Bicyclic Benzoheteroaromatic Compounds and Methods of Use Thereof

Application: 62/450,925 →

Fused Bicyclic Benzoheteroaromatic Compounds and Methods of Use Thereof

Patent: 11,274,093 →

Application: 16/480,211 →

Publication: US 2019/0367489

Fused N-Heterocyclic Compounds and Methods of Use Thereof

Application: 62/450,953 →

Fused N-Heterocyclic Compounds and Methods of Use Thereof

Application: 16/480,849 →

Publication: US 2020/0385364

Benzothiophene and Benzothiazole Compounds and Methods of Use Thereof

Application: 62/450,956 →

Benzothiophene and Benzothiazole Compounds and Methods of Use Thereof

Patent: 11,358,959 →

Application: 16/480,861 →

Publication: US 2019/0389851

Fused Hetero-Hetero Bicyclic Compounds and Methods of Use Thereof

Application: 62/450,962 →

Fused Hetero-Hetero Bicyclic Compounds and Methods of Use Thereof

Patent: 11,059,819 →

Application: 16/480,874 →

Publication: US 2019/0345158

Covalent Inhibitors of Kras

Application: 62/511,163 →

Covalent Inhibitors of Kras

Application: 62/625,889 →

Covalent Inhibitors of Kras

Patent: 10,745,385 →

Application: 15/989,015 →

Publication: US 2019/0062313

Covalent Inhibitors of Kras

Patent: 11,377,441 →

Application: 16/915,942 →

Publication: US 2021/0024501

Compounds and Methods of Use Thereof

Application: 62/511,152 →

Quinazoline Derivatives as Modulators of Mutant Kras, Hras or Nras

Patent: 11,639,346 →

Application: 16/616,066 →

Publication: US 2020/0115363

Compounds and Methods of Use Thereof for Treatment of Cancer

Application: 62/511,159 →

Compounds and Methods of Use Thereof for Treatment of Cancer

Application: 62/625,902 →

Compounds and Methods of Use Thereof for Treatment of Cancer

Patent: 10,736,897 →

Application: 15/989,031 →

Publication: US 2019/0062314

Compounds and Methods of Use Thereof for Treatment of Cancer

Application: 62/713,371 →

Compounds and Methods of Use Thereof for Treatment of Cancer

Application: 62/713,298 →

Compounds and Methods of Use Thereof for Treatment of Cancer

Application: 62/773,084 →

Compounds and Methods of Use Thereof for Treatment of Cancer

Application: 62/750,009 →

Compounds and Methods of Use Thereof for Treatment of Cancer

Application: 62/773,104 →

Covalent Inhibitors of Kras G12C

PCT: PCT/US2014/027504 ↗

Inhibitors of Kras G12C

PCT: PCT/US2014/060036 ↗

Combination Therapies for Treatment of Cancer

PCT: PCT/US2015/051030 ↗

Inhibitors of Kras G12C Mutant Proteins

PCT: PCT/US2015/052349 ↗

Substituted Quinazoline Compounds and Methods of Use Thereof

PCT: PCT/US2016/026573 ↗

Substituted Quinazoline Compounds and Methods of Use Thereof

PCT: PCT/US2016/043568 ↗

Methods for Preparation of Quinazoline Derivatives

PCT: PCT/US2016/065786 ↗

2-Substituted Quinazoline Compounds Comprising a Substituted Heterocyclic Group and Methods of Use Thereof

PCT: PCT/US2016/062288 ↗

Inhibitors of Ras and Methods of Use Thereof

PCT: PCT/US2017/055656 ↗

Inhibitors of Kras G12C Mutant Proteins

PCT: PCT/US2017/054363 ↗

Covalent Inhibitors of Kras

PCT: PCT/US2018/034471 ↗

Compounds and Methods of Use Thereof for Treatment of Cancer

PCT: PCT/US2018/034473 ↗

Compounds and Methods of Use Thereof for Treatment of Cancer

PCT: PCT/US2019/044729 ↗

Compounds and Methods of Use Thereof for Treatment of Cancer

PCT: PCT/US2019/063702 ↗

Compounds and Methods of Use Thereof for Treatment of Cancer

PCT: PCT/US2019/057694 ↗

Related Assignments (19)

Other recorded transfers of the patents in this record — the chain of ownership.

Assignment of Assignor's Interest Apr 18, 2013

From: REN, PINGDA; LIU, YI; LI, LIANSHENG; FENG, JUN

To: ARAXES PHARMA LLC

Reel/Frame 030248/0015 →

Assignment of Assignor's Interest Apr 18, 2013

From: REN, PINGDA; LIU, YI; LI, LIANSHENG; FENG, JUN

To: ARAXES PHARMA LLC

Reel/Frame 030247/0996 →

Assignment of Assignor's Interest Dec 4, 2013

From: REN, PINGDA; LIU, YI; LI, LIANSHENG; FENG, JUN

To: ARAXES PHARMA LLC

Reel/Frame 031713/0333 →

Assignment of Assignor's Interest Dec 4, 2013

From: LI, LIANSHENG; FENG, JUN; WU, TAO; REN, PINGDA

To: ARAXES PHARMA LLC

Reel/Frame 031713/0500 →

Assignment of Assignor's Interest Dec 4, 2013

From: REN, PINGDA; LIU, YI; LI, LIANSHENG; FENG, JUN

To: ARAXES PHARMA LLC

Reel/Frame 031713/0071 →

Assignment of Assignor's Interest Sep 24, 2014

From: LI, LIANSHENG; FENG, JUN; WU, TAO; REN, PINGDA

To: ARAXES PHARMA LLC

Reel/Frame 033808/0455 →

Assignment of Assignor's Interest Sep 26, 2014

From: LI, LIANSHENG; FENG, JUN; WU, TAO; REN, PINGDA

To: ARAXES PHARMA LLC

Reel/Frame 033830/0356 →

Assignment of Assignor's Interest Nov 13, 2014

From: LI, LIANSHENG; FENG, JUN; REN, PINGDA; LIU, YI

To: ARAXES PHARMA LLC

Reel/Frame 034162/0625 →

Assignment of Assignor's Interest Feb 23, 2015

From: REN, PINGDA; LIU, YI; LI, LIANSHENG; FENG, JUN

To: ARAXES PHARMA LLC

Reel/Frame 035009/0071 →

Assignment of Assignor's Interest May 18, 2015

From: LI, LIANSHENG; FENG, JUN; WU, TAO; REN, PINGDA

To: ARAXES PHARMA LLC

Reel/Frame 035660/0350 →

Assignment of Assignor's Interest Jun 16, 2015

From: JANES, MATTHEW ROBERT; PATRICELLI, MATTHEW PETER; LI, LIANSHENG; REN, PINGDA

To: ARAXES PHARMA LLC

Reel/Frame 035923/0941 →

Assignment of Assignor's Interest Aug 27, 2015

From: JANES, MATTHEW ROBERT; PATRICELLI, MATTHEW PETER; LI, LIANSHENG; REN, PINGDA

To: ARAXES PHARMA LLC

Reel/Frame 036443/0236 →

Assignment of Assignor's Interest Nov 10, 2015

From: LI, LIANSHENG; FENG, JUN; LONG, YUN OLIVER; REN, PINGDA

To: ARAXES PHARMA LLC

Reel/Frame 037085/0759 →

Assignment of Assignor's Interest Jan 8, 2016

From: LI, LIANSHENG; FENG, JUN; REN, PINGDA; LIU, YI

To: ARAXES PHARMA LLC

Reel/Frame 037442/0871 →

Assignment of Assignor's Interest Mar 2, 2016

From: JANES, MATTHEW ROBERT; PATRICELLI, MATTHEW PETER; LI, LIANSHENG; REN, PINGDA

To: ARAXES PHARMA LLC

Reel/Frame 037875/0569 →

Assignment of Assignor's Interest Mar 28, 2016

From: REN, PINGDA; LI, YI; LI, LIANSHENG; FENG, JUN

To: ARAXES PHARMA LLC

Reel/Frame 038274/0974 →

Assignment of Assignor's Interest Aug 26, 2016

From: LI, LIANSHENG; FENG, JUN; LONG, YUN OLIVER; REN, PINGDA

To: ARAXES PHARMA LLC

Reel/Frame 039850/0808 →

Assignment of Assignor's Interest May 30, 2018

From: LI, LIANSHENG; FENG, JUN; LONG, YUN OLIVER; REN, PINGDA

To: ARAXES PHARMA LLC

Reel/Frame 045938/0904 →

Assignment of Assignor's Interest May 27, 2021

From: ARAXES PHARMA LLC

To: ARAXES PHARMA LLC; JANSSEN BIOTECH, INC.

Reel/Frame 056969/0864 →